Related by context. All words. (Click for frequent words.) 68 CATIE AD 68 glatiramer acetate 67 Sibutramine Cardiovascular Outcomes 67 blinded randomized placebo controlled 67 BRIM3 67 CHAMPION PCI 66 recurrent glioblastoma multiforme 66 AIM HIGH 66 DAPT 66 relapsed MM 66 multicenter randomized controlled 66 AVERROES 66 Intervention Effectiveness CATIE 66 Randomized controlled 66 XL# SAR# 65 Randomised 65 Intervention Effectiveness 65 selenium supplementation 65 phase Ib 65 multicentre randomized 65 multicenter randomized placebo controlled 65 desvenlafaxine succinate 65 STRIDE PD 65 phase IIa clinical 65 Phase Ib clinical 65 ONTARGET 65 MADIT II 64 Phase IIIb clinical 64 phase IIa 64 ocrelizumab 64 Phase III randomized controlled 64 Capesaris 64 Ziprasidone 64 RhuDex 64 Randomized Evaluation 64 BCIRG 64 dose escalation clinical 64 HCV SPRINT 64 multicenter placebo controlled 64 pivotal bioequivalence 64 MIRAPEX ER 64 oral rivaroxaban 64 Clinical Antipsychotic Trials 64 assessing T DM1 64 Teriflunomide 64 Xelox 64 dose escalation phase 64 Certolizumab pegol 64 BRIM2 63 phase IIb study 63 riociguat 63 placebo controlled clinical 63 FASLODEX 63 MAGE A3 ASCI 63 CHARM Added 63 multicenter Phase 63 lacosamide 63 RE LY 63 landmark ATHENA 63 prospective nonrandomized 63 Celecoxib APC trial 63 interferon gamma 1b 63 phase IIIb 63 Glucosamine Chondroitin Arthritis 63 phase IIb clinical 63 Phase #/#a 63 Carotid Revascularization Endarterectomy vs. 63 PD LID 63 CLARITY study 63 Adenoma Prevention 63 ACCOMPLISH 63 regorafenib 63 divalproex sodium 63 Ophena TM 63 CIMZIA TM certolizumab pegol 63 Femara letrozole 63 multicenter randomized clinical 63 PreCISe 63 Dose escalation 63 SWOG 63 MEND CABG 63 icatibant 62 EURIDIS 62 abacavir Ziagen 62 figitumumab 62 boosted protease inhibitor 62 nonrandomized 62 alvespimycin 62 ADAGIO study 62 OPT CHF 62 irbesartan 62 visilizumab 62 double blinded placebo 62 ONCONASE R 62 APEX AMI 62 avosentan 62 RE MODEL 62 Prostate AdenoCarcinoma Treatment 62 CYT# QbG# 62 confirmatory clinical 62 ibandronate 62 ziprasidone 62 CAMMS# 62 phase IIb 62 goserelin 62 Phase IIb III 62 abacavir lamivudine 62 registrational Phase 62 Aflibercept 62 tarenflurbil 62 galiximab 62 CARE HF 62 acyclovir Lauriad R 62 ORAL Sync 62 PEARL SC 62 RLAI 62 AVADO 62 multicentre randomized controlled 62 ACTEMRA TM 62 β blockers 62 randomized multicenter trial 62 lipid lowering therapy 62 midstage clinical 62 antiarrhythmic drug 62 prospective multicentre 62 randomized blinded 62 prospective randomized placebo 62 Subgroup analysis 62 Perforomist Inhalation Solution 62 Temsirolimus 62 prucalopride 62 cilostazol 62 randomized controlled Phase 62 Exemestane 61 ADVANCE PD 61 Apixaban 61 pramlintide metreleptin combination 61 HCV RESPOND 2 61 BYSTOLIC 61 randomized Phase IIb 61 brivaracetam 61 ximelagatran 61 RRMS patients 61 HF ACTION 61 viral kinetic 61 Fulvestrant 61 tenofovir emtricitabine 61 LUX Lung 61 ASTEROID 61 Multicenter Automatic Defibrillator Implantation 61 Phase Ib II 61 ARIMIDEX 61 fosbretabulin 61 tanespimycin 61 randomized crossover 61 tocilizumab 61 decitabine 61 intensive lipid lowering 61 NP2 Enkephalin 61 triple nucleoside 61 FDA defined valvulopathy 61 randomized multicenter 61 Degarelix 61 evaluating Actimmune 61 unfractionated heparin UFH 61 BENICAR HCT 61 insulin detemir 61 enzastaurin 61 Dabigatran 61 ATACAND 61 Phase 1a clinical 61 direct thrombin inhibitors 61 CIMZIA TM 61 paricalcitol 61 GOUT 61 Mylotarg 61 gemcitabine Gemzar ® 61 genotypic resistance 61 EchoCRT 61 Arranon 61 ACCORD Lipid 61 6R BH4 61 Dacogen injection 61 teriflunomide 61 Hormone Refractory Prostate Cancer 61 multicenter prospective 61 Refractory Angina 61 Phase Ib study 61 placebo controlled randomized 61 Randomized Phase II 61 strontium ranelate 61 SYMMETRY trial 61 APEX PD 61 Cholesterol Levels SPARCL 61 GW# [003] 61 ZACTIMA 61 RE LY ® 61 LUMINATE 61 relapsing remitting MS RRMS 61 tramiprosate Alzhemed TM 61 randomized multicentre 61 multicenter Phase II 61 Dasatinib 61 biliary tract cancer 61 RSD# oral 61 aspirin clopidogrel 61 Velcade bortezomib 61 paclitaxel poliglumex 61 amisulpride 61 Aggressive Reduction 61 Initiated Phase 61 QLT# 61 agomelatine 61 antihypertensive therapy 61 vidofludimus 61 CALGB # [002] 61 Betaferon R 61 PEG interferon 61 DEB# 61 Randomized Double blind 61 Sprycel dasatinib 61 ZOLINZA 61 REVIVE Diabetes 61 INSPIRE Trial Phase III 61 MGd 61 pharmacodynamics PD 61 Stenting Trial CREST 61 rFVIIa 61 Hydroxyurea 61 CALGB # [001] 61 MEVACOR 61 Randomized Phase 61 Motesanib 61 EDARBI 61 GSK# [001] 61 SPIRIT FIRST 61 APPRAISE 61 Fondaparinux 60 AZILECT R 60 olmesartan 60 ECASS 60 multidose 60 viral kinetics 60 PRIMO CABG 60 double blinded randomized 60 Randomized placebo controlled 60 Prostate Cancer Prevention 60 Bifeprunox 60 CALGB 60 DSMB recommended 60 Edge STudy 60 evaluating tivozanib 60 Vorapaxar 60 Celebrex celecoxib 60 motesanib diphosphate 60 PREZISTA r 60 PRoFESS 60 IMPACT DCM 60 ARBITER 6 60 muraglitazar 60 pentoxifylline 60 CLARITY TIMI 60 NSABP B 60 Teysuno 60 VIRAMUNE XR 60 trials RCTs 60 baminercept 60 MIST II 60 MERLIN TIMI 60 pertuzumab 60 nab paclitaxel 60 RIO Lipids 60 Exforge HCT 60 ezetimibe simvastatin 60 erlotinib Tarceva 60 clomipramine 60 HYVET 60 aldosterone antagonists 60 Betaferon ® 60 canakinumab 60 multicenter Phase III 60 oral FTY# 60 TACI Ig 60 cediranib 60 tolvaptan 60 Traficet EN 60 ULORIC 60 Placebo controlled 60 sargramostim 60 placebo controlled Phase 60 celecoxib Celebrex 60 immunomodulatory agents 60 label multicenter randomized 60 NSABP C 60 ritonavir boosted atazanavir 60 ExTRACT TIMI 60 Afatinib 60 trastuzumab Herceptin ® 60 neratinib 60 Enzastaurin 60 Pemetrexed 60 placebo controlled multicenter 60 APTIVUS 60 anastrazole 60 antidepressants fluoxetine 60 NSABP 60 APEX AMI trial 60 Adjuvant chemotherapy 60 AOD# [002] 60 AA Amyloidosis 60 COREG 60 rosuvastatin Crestor 60 alkylating agent 60 Folfox 60 velafermin 60 BRAF inhibitor 60 Pivotal Phase III 60 metastatic RCC 60 thalidomide Thalomid 60 sunitinib malate 60 MDV# 60 Secondary efficacy endpoints 60 subcutaneous PRO 60 randomized controlled multicenter 60 PFO migraine 60 thorough QT 60 eosinophilic asthma 60 LibiGel Phase III 60 AKT inhibitor 60 subcutaneously administered 60 cangrelor 60 Phase Ib IIa 60 Dalbavancin 60 prospective randomized multicenter 60 ritonavir boosted 60 Phase IIA 60 TLK# 60 TMC# C# 60 HuMax EGFr 60 Phase IIB 60 interferon beta 1b 60 efavirenz EFV 60 blinded randomized 60 pharmacokinetic characteristics 60 sorafenib Nexavar 60 Quinamed 60 TRA 2P 60 prospective randomized controlled 60 concurrent chemoradiation 60 SIMPADICO 60 number NCT# ClinicalTrials.gov 60 DU #b 60 Truvada tablets 60 beta blocker therapy 60 active comparator 60 atorvastatin Lipitor 60 oral ridaforolimus 60 AIR CF1 60 Toremifene 60 metastatic colorectal carcinoma 60 randomized controlled clinical 60 AGILECT R 60 HGS# 60 Phase #b/#a 60 selective COX 2 60 tesmilifene 60 Phase IIa trials 60 zonisamide SR 60 eplerenone 60 AZILECT ® 60 HORIZONS AMI trial 60 cholinesterase inhibitors 60 Phase III placebo controlled 60 multicenter clinical 60 cabazitaxel 60 temsirolimus 59 dual endothelin receptor antagonist 59 oral anticoagulation 59 EVEREST II 59 donepezil Aricept 59 Androxal TM 59 leflunomide 59 NATRECOR ® 59 Elocalcitol 59 MIRAPEX 59 designated HVTN 59 ginkgo extract 59 CIMZIA R 59 epoetin alpha 59 opioid induced bowel dysfunction 59 multicenter randomized Phase 59 dosing cohort 59 VADT 59 Tyrima 59 TORISEL TM 59 prospective multicenter randomized 59 lapatinib Tykerb 59 dose titration 59 GnRH agonists 59 AIR CF2 59 treatment naive genotype 59 Zemplar Capsules 59 diabetic gastroparesis 59 postmenopausal osteoporotic women 59 Scandinavian Simvastatin Survival 59 Natalizumab 59 HOPE TOO 59 prospectively stratified 59 Pharmacokinetics PK 59 davalintide 59 ancrod 59 bevacizumab Avastin 59 aprepitant 59 iniparib 59 randomized clinical 59 placebo controlled Phase III 59 PPAR gamma agonist 59 5 fluorouracil leucovorin 59 CYT# potent vascular disrupting 59 Oral Fingolimod 59 Liraglutide Effect 59 Relapsing Multiple Sclerosis 59 PLCO 59 CHAMPION PLATFORM 59 ToGA 59 pegaptanib 59 EOquin TM 59 carotid artery stenting CAS 59 metastatic hormone refractory 59 SUTENT ® 59 miglustat 59 Torisel 59 Tanespimycin 59 RECORD1 59 leukotriene receptor antagonist 59 CBLC# 59 titrated glipizide 59 trastuzumab DM1 59 pomalidomide 59 rufinamide 59 citalopram Celexa 59 HPTN 59 neurologic progression 59 Primary endpoints 59 atazanavir ritonavir 59 Raloxifene STAR 59 ChronVac C ® 59 GAMMAGARD 59 neoadjuvant 59 ELACYT 59 elotuzumab 59 mycophenolate mofetil MMF 59 pimozide 59 castrate resistant prostate cancer 59 Tolvaptan 59 carotid endarterectomy CEA 59 Avanafil 59 pregabalin 59 talabostat 59 ABVD 59 anastrozole 59 Bioequivalence 59 prospective observational studies 59 pravastatin Pravachol 59 antioxidant supplementation 59 neoadjuvant treatment 59 clevidipine 59 eprotirome 59 CsA 59 fondaparinux 59 Ranolazine 59 recurrent malignant glioma 59 Aplidin 59 Deforolimus 59 biologic DMARD 59 lumiliximab 59 HBeAg negative patients 59 EDEMA3 59 Percutaneous Tibial Nerve Stimulation 59 fluvastatin Lescol 59 antithrombotic 59 Phase 2b kidney transplant 59 Ocrelizumab 59 Phase Ib 59 PANVAC VF 59 selective androgen receptor modulator 59 #mg dosing 59 systemic corticosteroid 59 Laquinimod 59 pyridostigmine 59 aripiprazole Abilify 59 Neoadjuvant 59 ARIXTRA 59 adalimumab Humira 59 #mg/day [001] 59 TWYNSTA 59 candesartan cilexetil 59 HMG CoA reductase inhibitors 59 CALERIE 59 doxorubicin Adriamycin 59 infliximab Remicade 59 blinded placebo controlled 59 BAL# [002] 59 ENDEAVOR III 59 balsalazide tablet 59 Double Blind Randomized 59 miconazole Lauriad ® 59 anakinra 59 ENGAGE AF TIMI 59 mapatumumab 59 APTIVUS r 59 exemestane 59 gadobutrol 59 glatiramer acetate Copaxone 59 orBec 59 aleglitazar 59 randomized Phase III 59 receptor tyrosine kinase inhibitor 59 CUSTOM III 59 unblinding 59 ASCEND HF 59 Board DSMB 59 Amrubicin 59 Acute Coronary Syndromes ACS 59 adjuvant endocrine therapy 59 beta 1a 59 mycophenolate mofetil 59 Mirapexin 59 multicenter phase 59 phase IIb III 59 tasocitinib 59 CombAT 59 Tocilizumab 59 Phase III ADT 59 Phase 2a trial 59 guanfacine extended release 59 chemoradiation therapy 59 biologic DMARDs 59 senicapoc 59 bosentan 59 Azacitidine 59 azilsartan medoxomil 59 pegylated interferon alfa 2b 59 3TC lamivudine Epivir 59 Cytoxan 59 TDF FTC 59 BZA CE 59 Phase #b/#a trial 59 adalimumab 59 CCX# B 59 intravenous dosing 59 PA# [002] 59 LEXIVA r 59 tipranavir ritonavir 59 BOLDER II 59 KRN# 59 NOX E# 59 ONTARGET R 59 antidiabetic drug 59 SPARCL 59 doxorubicin cyclophosphamide 59 Phase III randomized 58 glucocorticoid induced osteoporosis 58 PSMA ADC 58 concurrent ITP 58 EMPHASIS HF trial 58 efalizumab 58 ongoing Phase 1b 58 levodopa induced dyskinesia 58 Neuvenge 58 tramiprosate ALZHEMED TM 58 substudy 58 Prospective Randomized 58 TREDAPTIVE 58 Trandolapril 58 Ophena 58 Cardiotoxicity 58 phase III isavuconazole 58 lipid lowering drugs 58 ENESTnd 58 antiplatelet agent 58 Lamictal XR 58 AVOREN 58 Fluvastatin 58 YONDELIS 58 ALLHAT 58 COPAXONE R 58 ChronVac C R 58 ritonavir boosted lopinavir 58 Alpha Tocopherol Beta Carotene 58 prospectively defined 58 VELCADE melphalan 58 idraparinux 58 WX UK1 58 raloxifene Evista 58 noninferiority 58 Glufosfamide 58 DFMO 58 iPrEx 58 Pimavanserin 58 BEXXAR Therapeutic Regimen 58 bupropion XL 58 TroVax ® 58 RhuDex TM 58 GVAX 58 coxib 58 Ceplene/IL-2 58 ALTACE R 58 Lovastatin 58 Phase 2b clinical 58 chemoradiotherapy 58 VA# [002] 58 Randomized Double Blind 58 Plicera 58 pharmacokinetics PK 58 paroxetine Paxil 58 clopidogrel Plavix 58 Epirubicin 58 lenalidomide dexamethasone 58 Bivalirudin 58 NeuroVax 58 Thrombolysis 58 preoperative chemotherapy 58 IIa trial 58 nucleotide analogue 58 BARI 2D 58 crizotinib PF # 58 FOLPI 58 ixabepilone 58 EndoTAG TM -1 58 idarubicin 58 TBC# 58 CYP#D# inhibitor 58 Phase IIIb 58 darunavir ritonavir 58 platelet inhibitor 58 Phase 1b clinical trials 58 Intervention Trial GAIT 58 metastatic castration resistant 58 prostate cancer mCRPC 58 Cimzia TM 58 galantamine 58 modified REGENESIS Phase IIb 58 ADMIRE HF 58 worsening thrombocytopenia 58 metreleptin 58 paclitaxel Taxol 58 HCl capsules 58 multicentre 58 Multiple Ascending Dose 58 metastatic malignant 58 biologic therapy 58 acute mania 58 relapsing MS 58 androgen suppression 58 antithrombotic therapy 58 Fingolimod 58 pegylated liposomal doxorubicin 58 bepotastine besilate nasal spray 58 Phase IIb clinical 58 serotonin norepinephrine reuptake inhibitor 58 de novo kidney transplant 58 plus prednisone 58 Telmisartan 58 label multicenter Phase 58 TAXUS VI 58 ACAPODENE 58 thromboembolic 58 acute gout 58 Sorafenib HCC Assessment 58 subanalysis 58 recurrent glioma 58 FAMPYRA 58 Paxil paroxetine 58 Daclizumab 58 pharmacodynamic effects 58 TYGACIL 58 MVax 58 Pivotal Phase 58 antiretroviral naive 58 PROactive study 58 Fibrillex TM 58 salmeterol fluticasone 58 MADIT 58 AZT zidovudine Retrovir 58 LAB CGRP 58 Certolizumab 58 dexpramipexole 58 CHOP chemotherapy 58 mRCC 58 placebo controlled clinical trials 58 prospective multicenter 58 ABSORB trial 58 MEND CABG II 58 NATRECOR R 58 ritonavir boosted danoprevir 58 placebo controlled 58 rNAPc2 58 somatostatin analog 58 dorzolamide 58 ALVESCO R 58 long acting bronchodilator 58 TAXUS IV 58 Pafuramidine 58 bendamustine 58 Cladribine tablets 58 recurrent metastatic 58 blinded placebo 58 FOSRENOL ® 58 postoperative AF 58 PROTECT II 58 multicentre randomized double 58 Proellex TM 58 BCR ABL inhibitor 58 dalteparin 58 Double Blind Placebo 58 MULTAQ 58 antiandrogen 58 doxorubicin docetaxel 58 CINQUIL 58 Phase III VISTA 58 IMPACT IMmunotherapy 58 GFT# 58 noscapine 58 tacrolimus ointment 58 metastatic GIST 58 BETAS 58 Zarnestra 58 metastatic CRPC 58 mg RDEA# 58 WHIMS 58 PF # [002] 58 Ropinirole 58 EVIZON 58 PegIFN RBV 58 alvimopan 58 pharmacologic treatments 58 docetaxel chemotherapy 58 phase IIb trial 58 mg/m2 cohort 58 Subgroup analyzes 58 Targretin capsules 58 NCT# ClinicalTrials.gov 58 Hepatotoxicity 58 ribavirin RBV 58 mg TID 58 tolterodine 58 Antihypertensive 58 SYN# 58 fluvastatin 58 ß blockers 58 + Perifosine Evaluation 58 adjuvant tamoxifen 58 venlafaxine XR 58 symptomatic hyponatremia 58 virus HCV protease inhibitor 58 anti Parkinsonian 58 evaluating REVLIMID 58 abiraterone acetate 58 alendronate Fosamax 58 OvaRex MAb 58 Pyridorin 58 EMPHASIS HF 58 Sapacitabine 58 Noxafil 58 Phase Ib IIa clinical 58 Ixabepilone 58 metastatic HRPC 58 Melphalan 58 phase Ib clinical 58 paclitaxel Taxol R 58 IMPACT DCM clinical 58 Mg Usa 58 comparator arm 58 rHuPH# 58 Intravitreal 58 Digital Mammographic Imaging 58 Abilify aripiprazole 58 Doxil ® 58 Pegylated Interferon 58 Xeloda ® 58 everolimus eluting stents 57 #mg BID [001] 57 ataluren 57 Bosutinib 57 Pertuzumab 57 antifibrinolytic 57 Phase IIb clinical trials 57 MIRCERA 57 VFEND 57 olaparib 57 ILLUMINATE 57 Aplidin R 57 PROTEGE 57 acute PAO 57 SCIg 57 sitaxsentan 57 alteplase 57 Teriparatide 57 dose dose escalation 57 bortezomib Velcade 57 ORENCIA ® 57 PREVENT IV 57 vandetanib 57 Decitabine 57 Alfimeprase 57 pramlintide metreleptin 57 multicenter randomized 57 NCCTG N# 57 SPRYCEL ® 57 AGILECT ® 57 RE LY trial 57 Diamyd r 57 venlafaxine ER 57 Fracture Intervention Trial 57 flutamide 57 bicalutamide 57 glatiramer acetate GA 57 TASKi3 57 Tarceva TM 57 Long Term Efficacy 57 nefazodone 57 Phase III Pivotal 57 Ixempra 57 recurrent GBM 57 coadministration 57 lexidronam injection 57 sipuleucel T 57 advanced metastatic prostate 57 Phase Ia 57 estramustine 57 keloid scarring 57 atrasentan 57 #:# randomization 57 certolizumab pegol 57 Initiate Phase 57 Phase III multicenter 57 Revlimid lenalidomide 57 multicenter randomized double 57 evaluating Nexavar 57 PEGINTRON TM 57 C2L 57 Mycophenolate Mofetil 57 desvenlafaxine 57 relapsing multiple sclerosis 57 chlorambucil 57 Oxypurinol 57 nucleoside analog 57 COSIRA trial 57 Rilonacept 57 ropinirole 57 ARCOXIA 57 placebo controlled studies 57 Phase IIIb study 57 Glatiramer Acetate 57 reslizumab 57 NCIC CTG 57 Jevtana 57 PEG SN# 57 Valdoxan 57 donepezil 57 PRT# 57 analgesic efficacy 57 Varenicline 57 nitazoxanide 57 CONQUER OB 57 tolevamer 57 beta carotene supplementation 57 capecitabine Xeloda 57 Simulect 57 DASISION 57 ENDEAVOR IV 57 Pooled Analysis 57 vicriviroc 57 Secondary endpoints 57 ROCKET AF 57 ACCORD Eye 57 Letrozole 57 lenalidomide Revlimid 57 warfarin therapy 57 INVEGA ® 57 5-FU/LV 57 placebo controlled trials 57 postmenopausal estrogen 57 PEGINTRON REBETOL combination 57 #mg QD [002] 57 ISENTRESS 57 Active Ulcerative Colitis 57 Glatiramer acetate 57 EGS# 57 Aliskiren 57 Irbesartan 57 Saxagliptin 57 GLP1 agonist 57 sulphonylureas 57 CIMZIA ™ 57 Fx #A 57 oral prodrug 57 EQUIP OB 57 demonstrated clinically meaningful 57 calcium antagonist 57 intravenous cyclophosphamide 57 TASKi2 57 IFN α 57 deferiprone 57 BENICAR 57 AZOR 57 PRE SURGE 57 ACCEDE 57 alefacept 57 FOSRENOL R 57 Controlled Trial 57 multicenter multinational 57 docetaxel Taxotere R 57 im peramivir 57 periprocedural MI 57 candesartan 57 Vildagliptin 57 CIPN 57 TAXOTERE R 57 canagliflozin 57 preclinical pharmacokinetic 57 Bosentan 57 pioglitazone hydrochloride 57 Ataluren 57 Severe Sepsis 57 zoledronic acid Zometa 57 ELND# 57 AVANDIA 57 TransVax 57 renoprotective 57 Candesartan 57 APTIVUS ritonavir 57 solanezumab 57 ganetespib 57 fenofibric acid 57 tirofiban 57 lenalidomide Revlimid R 57 pharmacokinetic PK 57 quadrivalent HPV vaccine 57 Adjuvant Treatment 57 interferon ribavirin 57 REALITY Trial 57 registrational trial 57 AVASTIN 57 glatiramer 57 Fixed Dose 57 SCH # 57 UVIDEM 57 corticosteroid therapy 57 Spine Patient Outcomes 57 hematologic parameters 57 angiotensin receptor 57 alpha 2a 57 Sym# 57 Alzhemed TM 57 calcineurin inhibitor 57 morphometric vertebral fractures 57 REMINYL ® 57 VICTOR E1 57 ospemifene 57 ACOMPLIA R 57 Lamotrigine 57 TELCYTA 57 Faslodex 57 Acute Myocardial Infarction 57 Nuvion 57 EFAPROXYN 57 Onrigin 57 Keppra XR 57 nicardipine 57 eszopiclone 57 lamotrigine 57 Novartis Zometa 57 oral vancomycin 57 DDP# 57 Phase IIb Trial 57 Myelodysplastic Syndrome MDS 57 SABCS 57 prazosin 57 Cloretazine ® 57 clinical pharmacology studies 57 mcg dose 57 pramlintide 57 antiretroviral naïve 57 bupropion SR 57 HORIZONS AMI 57 basiliximab 57 evaluating Vectibix 57 HIV HCV coinfected 57 NTx ® -# 57 interferon beta therapy 57 PRECISE Trial 57 COPERNICUS 57 cilengitide 57 ziconotide 57 haloperidol Haldol 57 zoledronic acid Reclast 57 headache nasopharyngitis